Evidence map›Paper›PMID 33627226›Full record

ArticleJournal of geriatric oncology2021

Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.

Andrew C Johns, Lai Wei, Madison Grogan, Rebecca Hoyd, John F P Bridges, Sandipkumar H Patel, Mingjia Li, Marium Husain, Kari L Kendra, Gregory A Otterson and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Andrew C JohnsDept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Lai WeiDept. of Biomedical Informatics, The Ohio State University, USA.
Madison GroganDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Rebecca HoydDept. of Biomedical Informatics, The Ohio State University, USA; Div. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
John F P BridgesDept. of Biomedical Informatics, The Ohio State University, USA; Dept. of Surgery, The Ohio State University Wexner Medical Center, USA.
Sandipkumar H PatelDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Mingjia LiDiv. of Hospital Medicine, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Marium HusainDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Kari L KendraDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Gregory A OttersonDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Jarred T BurkartColumbus Oncology and Hematology Associates, Columbus, OH, USA.
Ashley E RoskoDiv. of Hematology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Barbara L AndersenDept. of Psychology, The Ohio State University, USA.
David P CarboneDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Dwight H OwenDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Daniel J SpakowiczDept. of Biomedical Informatics, The Ohio State University, USA; Div. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA.
Carolyn J PresleyDiv. of Medical Oncology, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, USA. Electronic address: carolyn.presley@osumc.edu.
The Ohio State University Wexner Medical Center · USThe Ohio State University · USColumbus Oncology and Hematology Associates · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Translational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0M
Resiliency among Older Adults Receiving Lung Cancer Treatment: A Supportive Care Intervention StudyK76AG074923 · NIA · OHIO STATE UNIVERSITY · PI PRESLEY, CAROLYN · 2021 to 2025
$1.2M
Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Pilot Intervention StudyR03AG064374 · NIA · OHIO STATE UNIVERSITY · PI PRESLEY, CAROLYN · 2019 to 2020
$232k
NCATS NIH HHS UL1 TR002733NCI NIH HHS K12 CA133250NCI NIH HHS P30 CA016058NIA NIH HHS K76 AG074923NIA NIH HHS R03 AG064374
6 · The paper itself

Abstract

objectivesDespite growing evidence that checkpoint inhibitor immunotherapy (IO) toxicity is associated with improved treatment response, the relationship between immune-related adverse events (irAEs) and overall survival (OS) among older adults [age ≥ 70 years (y)] remains unknown. The study goal was to determine differences in OS based on age and ≥ grade 3 (G3) irAEs. MATERIALS AND

methodsThis was a retrospective cohort study of 673 patients with advanced cancer. Patients who received ≥1 dose of IO at our institution from 2011 to 2018 were eligible. The primary outcome was OS from the start of first line of IO treatment, compared between four patient groups stratified by age and ≥ G3 irAEs with adjustment for patient characteristics using a Cox proportional hazards model. RESULTS AND

conclusionAmong all 673 patients, 35.4% were ≥ 70y, 39.8% had melanoma, and 45.6% received single-agent nivolumab. Incidence and types of ≥G3 irAEs did not differ by age. Median OS was significantly longer for all patients with ≥G3 irAEs (unadjusted 21.7 vs. 11.9 months, P = 0.007). There was no difference in OS among patients ≥70y with ≥G3 irAEs (HR 0.94, 95% CI 0.61-1.47, P = 0.79) in the multivariable analysis. Patients <70y with ≥G3 irAEs had significantly increased OS (HR 0.33, 95% CI 0.21-0.52, P < 0.001). Younger patients, but not older adults, with high-grade irAEs experience strong survival benefit. This difference may be due to the toll of irAEs themselves or the effects of treatments for irAEs, such as corticosteroids. Factors impacting OS of older adults after irAEs must be determined and optimized.

Indexed as

ImmunotherapyMelanomaAgedHumansImmunologic FactorsNivolumabRetrospective StudiesImmunologic FactorsNivolumabCancerCheckpoint inhibitorsImmune-related adverse eventsOlder adultsOverall survivalToxicity

Identifiers

PMID33627226
PMCPMC8184608
OpenAlexW3131289431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.